Arvinas takes its Parkinson’s degrader to Seoul
Arvinas presented early biomarker data on ARV-102, an oral drug built to clear the LRRK2 protein, at a major Parkinson’s meeting. Five minutes. That’s the slot Arvinas was given to present late-breaking data from its Phase 1 trial of ARV-102 in people with Parkinson’s disease. The stage was the 2026
<p>Arvinas presented early biomarker data on ARV-102, an oral drug built to clear the LRRK2 protein, at a major Parkinson’s meeting. Five minutes. That’s the slot Arvinas was given to present late-breaking data from its Phase 1 trial of ARV-102 in people with Parkinson’s disease. The stage was the 2026</p>